Clinical Trial Update: Efficacy and Safety of Baricitinib in Neuromyelitis Optica Spectrum Disorders [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating the efficacy and safety of baricitinib in neuromyelitis optica spectrum disorder, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuromyelitis Optica Spectrum Disorder

Drugs mentioned

• Baricitinib (baricitinib)

Snippet

Sponsor: Tianjin Medical University General Hospital | Conditions: NMO Spectrum Disorder | Phase 1, Phase 2 | Status: RECRUITING